About
A focused platform company for
cell and gene therapy manufacturing
Femtobiomed develops CellShot, a non-viral gene delivery platform
built for CMC translation, regulatory readiness and efficient scale-up.
Company
Shaping the Future of
Non-Viral Cell Engineering
Mission
Advancing Cell Engineering into Scalable Therapies
Enable scalable and controllable non-viral gene delivery, compatible with real-world manufacturing and regulatory pathways.
Vision
Focused innovation where it matters most
To establish CellShot as a trusted global platform for non-viral cell engineering, addressing the most challenging steps in cell therapy manufacturing.
Electroporation is one of the most effective non-viral delivery tools—but controlling cellular stress remains the key challenge.
CellShot is engineered to address this challenge by reducing damage while preserving high-efficiency gene delivery.
Safety · Scalability · Precision · Integrity
At Femtobiomed, we advance non-viral cell engineering by redefining how genes are delivered with safety, control, and consistency. Through the CellShot® PFEP™ and Proliva™ platform, we enable scalable gene delivery while minimizing cellular damage—supporting reliable translation from research to manufacturing.
Our Team
Meet Our Team
History
CellShot® Commercialization
From Platform Innovation to Commercial Readiness
2021–Present | Commercialization of Second-Generation CellShot
From 2021, Femtobiomed advanced CellShot® into a second-generation platform through the development of its proprietary Partitioned Flow Electroporation (PFEP™) technology. In 2024, the CellShot Badger System was successfully registered with the U.S. FDA as a Drug Master File (DMF), establishing CellShot as a cGMP-ready non-viral gene delivery platform. In 2025, the Proliva™ buffer system was integrated into the CellShot Platform to further improve post-electroporation viability and gene insertion efficiency for CRISPR-based gene editing, as well as to enable precise and reproducible multi-pDNA delivery across diverse applications, including AAV manufacturing. 2025 marks a true inflection point in commercialization, with PFEP™, Proliva™, and Cryo-integrated processes—supported by proprietary patents—positioning CellShot as a next-generation platform for scalable cell and gene therapy manufacturing.
2021-2025
CellShot® Commercialization
Application Expansion through Proliva™ Integration Integrated the Proliva™ buffer system into the CellShot Platform, significantly improving post-electroporation viability and gene insertion efficiency. Expanded CellShot applications across CRISPR-based gene editing, precise multi-pDNA delivery, and advanced manufacturing workflows, including AAV production. Established an integrated PFEP™ + Proliva™ + Cryo workflow, marking a major inflection point in scalable non-viral cell and gene therapy manufacturing.
FDA DMF Registration & Clinical Collaboration Expansion Completed U.S. FDA DMF filing for the CellShot Badger System. Established strategic collaborations with Johns Hopkins University and Seoul St. Mary’s Hospital, including the launch of a high-efficiency mRNA gene delivery center. Secured Series D-2 funding led by Korea Investment Partners (KRW 3 billion).
CellShot Badger Launch & Regulatory Validation Launched the CellShot Badger System for non-viral gene delivery. Completed biocompatibility testing across seven categories in preparation for FDA DMF registration. Secured Series D-1 funding from SV Investment (KRW 2 billion).
Second-Generation PFEP Technology & Platform Expansion Filed core patents for second-generation CellShot PFEP technology and obtained NET certification. Launched the CellShot 3P TUI system and established a collaboration with The Catholic University of Korea. Completed Series C funding led by Ryukyung PSG (KRW 4 billion).
Foundation of Second-Generation CellShot Platform Registered the first-generation CellShot Nano-Injector patent in Japan. Initiated development of second-generation CellShot PFEP technology for mRNA transfection. Secured bridge funding from QUAD Investment Management and Widwin Investment (KRW 5 billion).